PEACE: Pediatric Antifungal Comparative Effectiveness

• Status: Completed
• Trial end date: 2018-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The overarching objective is to develop new evidence-based treatment guidelines for invasive fungal diseases in children. To accomplish that, this protocol will focus on two specific aims: 1) Compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis and for the subset of patients with invasive candidemia; 2) Characterize the incidence rate of inpatient pediatric invasive candidiasis per hospital admissions.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborators: Children's Hospital of Philadelphia; National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Amphotericin B; Antifungal Agents; Caspofungin; Clotrimazole; Fluconazole; Liposomal amphotericin B; Micafungin; Miconazole; Voriconazole

Criteria

Inclusion Criteria:

1. Males or females age > 120 days and <18 years

2. Documented proven or probable case of invasive candidiasis

3. Parental/guardian permission (informed consent, if required) and if appropriate, child assent (if required).

Exclusion Criteria:

1) Any history of prior Candida infection within the previous 35 days (These patients will not be eligible for analysis in aim 1 but will be eligible for inclusion of aim 2)